| Steroid biosynthesis |
2.18 |
0.00e+0 |
19/20 (95%) |
MSMO1;TM7SF2;SC5D;...
|
| Homologous recombination |
1.97 |
3.66e-3 |
35/41 (85.37%) |
RAD54B;RAD54L;MRE11;...
|
| Glycine, serine and threonine metabolism |
1.94 |
7.32e-3 |
31/40 (77.5%) |
CTH;SHMT1;CBS;...
|
| Citrate cycle (TCA cycle) |
1.74 |
4.03e-2 |
30/30 (100%) |
SUCLG1;DLST;IDH1;...
|
| Epstein-Barr virus infection |
-1.62 |
4.42e-2 |
189/202 (93.56%) |
TRAF6;SNW1;MDM2;...
|
| Basal cell carcinoma |
-1.63 |
4.49e-2 |
41/63 (65.08%) |
DDB2;TP53;APC;...
|
| T cell receptor signaling pathway |
-1.64 |
4.35e-2 |
93/104 (89.42%) |
CTLA4;PTPRC;PDPK1;...
|
| TGF-beta signaling pathway |
-1.65 |
3.97e-2 |
81/94 (86.17%) |
TGFB2;BMPR1A;TGFBR1;...
|
| Human T-cell leukemia virus 1 infection |
-1.65 |
4.13e-2 |
197/219 (89.95%) |
TGFB2;PRKACA;TGFBR1;...
|
| Ferroptosis |
-1.66 |
3.57e-2 |
36/41 (87.8%) |
SLC7A11;ACSL4;TP53;...
|
| Retinol metabolism |
-1.67 |
3.52e-2 |
41/68 (60.29%) |
UGT2A3;DHRS9;CYP2C18;...
|
| PD-L1 expression and PD-1 checkpoint pathway in cancer |
-1.67 |
3.56e-2 |
79/89 (88.76%) |
CSNK2A2;CHUK;ZAP70;...
|
| Transcriptional misregulation in cancer |
-1.71 |
2.30e-2 |
158/192 (82.29%) |
IL2RB;PTK2;BCL2L1;...
|
| AGE-RAGE signaling pathway in diabetic complications |
-1.71 |
2.41e-2 |
97/100 (97%) |
TGFB2;TGFBR1;COL1A2;...
|
| Cytokine-cytokine receptor interaction |
-1.72 |
2.23e-2 |
246/295 (83.39%) |
CXCR1;CXCR3;IL19;...
|
| Viral myocarditis |
-1.73 |
1.90e-2 |
53/60 (88.33%) |
HLA-DOB;CD40;CCND1;...
|
| NF-kappa B signaling pathway |
-1.75 |
1.54e-2 |
90/104 (86.54%) |
BIRC2;TRAF1;TRAF6;...
|
| Chronic myeloid leukemia |
-1.79 |
9.22e-3 |
72/76 (94.74%) |
GRB2;SHC1;MDM2;...
|
| IL-17 signaling pathway |
-1.79 |
9.79e-3 |
84/94 (89.36%) |
CCL2;TNF;CXCL10;...
|
| Staphylococcus aureus infection |
-1.82 |
8.04e-3 |
72/95 (75.79%) |
C1QB;FPR1;KRT17;...
|
| Hematopoietic cell lineage |
-1.86 |
4.31e-3 |
90/99 (90.91%) |
CD8A;CD37;CD34;...
|
| Viral protein interaction with cytokine and cytokine re... |
-1.92 |
9.27e-4 |
84/100 (84%) |
IL2RG;CCL2;CCR2;...
|
| Leishmaniasis |
-1.93 |
1.00e-3 |
67/77 (87.01%) |
TNF;IFNGR2;HLA-DOB;...
|
| Autoimmune thyroid disease |
-1.94 |
1.10e-3 |
46/53 (86.79%) |
HLA-F;CGA;HLA-DOB;...
|
| Bladder cancer |
-1.96 |
1.21e-3 |
40/41 (97.56%) |
E2F3;MAP2K1;TP53;...
|
| Th1 and Th2 cell differentiation |
-1.97 |
1.34e-3 |
80/92 (86.96%) |
IL2RB;CD3E;CD3D;...
|
| Th17 cell differentiation |
-2.02 |
0.00e+0 |
95/107 (88.79%) |
SMAD3;TGFB1;AHR;...
|
| Complement and coagulation cascades |
-2.09 |
0.00e+0 |
76/85 (89.41%) |
C1QA;SERPINF2;C8G;...
|
| Inflammatory bowel disease |
-2.12 |
0.00e+0 |
58/65 (89.23%) |
TLR5;STAT6;TGFB2;...
|
| Graft-versus-host disease |
-2.13 |
0.00e+0 |
32/42 (76.19%) |
HLA-F;TNF;HLA-DOB;...
|
| Systemic lupus erythematosus |
-2.20 |
0.00e+0 |
45/135 (33.33%) |
C1QA;C8G;C1QB;...
|
| Allograft rejection |
-2.22 |
0.00e+0 |
32/38 (84.21%) |
HLA-F;TNF;HLA-DOB;...
|
| Type I diabetes mellitus |
-2.29 |
0.00e+0 |
38/43 (88.37%) |
HLA-F;TNF;HLA-DOB;...
|
| Asthma |
-2.40 |
0.00e+0 |
25/31 (80.65%) |
TNF;FCER1A;HLA-DOB;...
|
